Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 38INDUSTRY 21NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Immunoglobulin Light-chain Amyloidosis 2Purpura 1Nausea 1Macroglossia 1Lymphadenopathy 1Hepatomegaly 1Gastrointestinal Hemorrhage 1Diarrhea 1Constipation 1Amyloidosis 1

Interventions

Dexamethasone 45Bortezomib 21Lenalidomide 19Cyclophosphamide 19daratumumab 16Calcium Dobesilate 13Thalidomide 12Melphalan 11carfilzomib 9Prednisone 7pomalidomide 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6Filgrastim 5dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Vincristine 4isatuximab 3Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2Steroids 2Radiotherapy 2Microarray Analysis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Multiple Myeloma × isatuximab × Clear all
NCT06182774 2026-05-12

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Canadian Cancer Trials Group

Phase 3 Recruiting
570 enrolled
Plasma cell

Multiple Myeloma

NCT05123131 2025-07-08

Isa-RVD

Cancer Trials Ireland

Phase 2 Active not recruiting
54 enrolled
Plasma cell

Multiple Myeloma

NCT04934475 2024-11-07

MIDAS

Intergroupe Francophone du Myelome

Phase 3 Active not recruiting
791 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡